Drugs

Article	Citations
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	471
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	407
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	245
Targeting DNA Damage Response Deficiency in Thoracic Cancers	216
New Therapies on the Horizon for Primary Biliary Cholangitis	213
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,	197
Eftrenonacog Alfa: A Review in Haemophilia B	189
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	162
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms	151
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	149
Acknowledgement to Referees	142
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	132
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	129
Aprocitentan: First Approval	129
Vorasidenib: First Approval	127
Senaparib: First Approval	120
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	117
Teclistamab: First Approval	112
Spesolimab for the Treatment of Generalized Pustular Psoriasis	111
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	108
Epcoritamab: First Approval	108
Ivarmacitinib Sulfate: First Approval	105
Olipudase Alfa: First Approval	102
Cosibelimab: First Approval	102
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms	96

Tolebrutinib: First Approval	92
Drugs in Development to Manage Acute Pain	91
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	88
Lenacapavir: First Approval	88
Danicopan: First Approval	88
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	86
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	85
Repotrectinib: First Approval	85
Acoltremon: First Approval	84
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	84
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	83
Androgenetic Alopecia: Therapy Update	80
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	80
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	78
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	73
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	73
Mazdutide: First Approval	72
Cancer Pain Treatment Strategies in Patients with Cancer	70
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	69
Mosunetuzumab: First Approval	69
Olverembatinib: First Approval	68
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	67
Managing Burning Mouth Syndrome: Current and Future Directions	67
Correction to: Tapinarof Cream 1%: First Approval	65
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	65
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	64
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	64
Correction to: Prevention and Treatment of Monkeypox	61
Taletrectinib: First Approval	60
Sunvozertinib: First Approval	59
The Place of Cannabinoids in the Treatment of Gynecological Pain	59
Dorzagliatin: First Approval	58
Pozelimab: First Approval	58
Tovorafenib: First Approval	57
Ifupinostat: First Approval	57
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	56
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	56
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	53
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	53
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	51
Correction to: Concizumab: First Approval	51
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies	50
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	49
Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib	49
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	49
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	48
Correction to: Remdesivir: A Review in COVID-19	48
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	47
Tirzepatide: A Review in Type 2 Diabetes	46
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review	46

Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	46
Birch Bark Extract: A Review in Epidermolysis Bullosa	45
Aumolertinib: A Review in Non-Small Cell Lung Cancer	45
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	44
Givinostat: First Approval	44
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	43
Asciminib: First Approval	43
Gepirone Extended-Release: First Approval	43
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	41
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	41
Ozoralizumab: First Approval	41
Catumaxomab: First Approval	41
Atrasentan: First Approval	39
Correction: Teprotumumab: A Review in Thyroid Eye Disease	39
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency	39
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	38
Fezolinetant: First Approval	38
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	37
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	37
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	37
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	37
Ensitrelvir Fumaric Acid: First Approval	37
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	36
Futibatinib: First Approval	36
Avacincaptad Pegol: First Approval	36
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	35
Correction: Iptacopan: First Approval	34
Eye Involvement and Management in Inherited Epidermolysis Bullosa	34
Lotilaner Ophthalmic Solution 0.25%: First Approval	34
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	34
Imetelstat: First Approval	34
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	34
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	34
Managing Pain in Fibromyalgia: Current and Future Options	33
Zeprumetostat: First Approval	33
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	33
Beremagene Geperpavec: First Approval	32
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	32
Zastaprazan: First Approval	32
Gastrointestinal Dysfunction in Parkinson’s Disease	32
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	32
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	32
Tebentafusp: First Approval	32
Acknowledgement to Referees	31
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	31
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	30
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	30
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	30
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	30
Mavorixafor: First Approval	30
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	30
Retifanlimab: First Approval	30
Crinecerfont: First Approval	30
Revumenib: First Approval	29
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	29
Sepiapterin: First Approval	29
Nogapendekin alfa Inbakicept: First Approval	29
Diagnosis and Treatment of AL Amyloidosis	29
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	28
Correction to: Abrocitinib: First Approval	28
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	28
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	27
Correction to: Spesolimab: First Approval	27
Correction: Zastaprazan: First Approval	27
Ravulizumab: A Review in Generalised Myasthenia Gravis	27
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	27
Correction to: Sparsentan: First Approval	27
Onradivir: First Approval	27
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	27
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	26
Methadone for Cancer Pain Management in Children: A Review of Literature	26
Zolbetuximab: First Approval	26
Remdesivir: A Review in COVID-19	26
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	26
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	26
Keverprazan Hydrochloride: First Approval	26
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	25
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	25
Lecanemab: First Approval	25
Marstacimab: First Approval	25

Daridorexant: First Approval	25
Molnupiravir: First Approval	25
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases	25
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review	25
Antibacterials with Novel Chemical Scaffolds in Clinical Development	25
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old	25
Spesolimab: First Approval	24
Nadofaragene Firadenovec: First Approval	24
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	24
Gefapixant: First Approval	24
Correction to: Mavacamten: First Approval	24
Elranatamab: First Approval	24
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	24
Pucotenlimab: First Approval	23
Correction to: Rozanolixizumab: First Approval	23
Tixagevimab + Cilgavimab: First Approval	23
Comment on: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	23
Eplontersen: First Approval	22
Comment on “Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review”	22
Tofersen: First Approval	22
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study	22
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions	22
Trastuzumab Rezetecan: First Approval	22
Amubarvimab/Romlusevimab: First Approval	22
Ritlecitinib: First Approval	22
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline	21
Gepotidacin: First Approval	21
Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’	21
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition	21
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders	21
Correction to: Ozanimod: A Review in Ulcerative Colitis	21
Elafibranor: First Approval	20
Differentiating IL-23 Inhibitors in Crohn’s Disease	20
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis	20
New Developments in Glucagon Treatment for Hypoglycemia	20
Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don’t Know	20
Paltusotine: First Approval	20
Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective	19
Talquetamab: First Approval	19
PCSK9 Inhibitors: A Potential Priority Choice for Lipid Management in Patients with Diabetic Kidney Disease	19
Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments	19
Valoctocogene Roxaparvovec: First Approval	19
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	18
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?	18
Motixafortide: First Approval	18
Iptacopan: First Approval	18
Sulbactam/Durlobactam: First Approval	18
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort St	18
Sipavibart: First Approval	18
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	18
Vamorolone: First Approval	18
PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis	18
Tunlametinib: First Approval	18
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy	18
Correction: Senaparib: First Approval	18
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	18
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	18
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	17
Tirzepatide: First Approval	17
Vimseltinib: First Approval	17
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	17
Dimdazenil: First Approval	17
Mirvetuximab Soravtansine: First Approval	17
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	17
Authors’ Reply to Colak et al.: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	17
Linzagolix: First Approval	16
Nemolizumab: First Approval	16
Drug-Induced Pigmentation: A Review	16
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy	16
Results from Expanded Access Programs: A Review of Academic Literature	16
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	16
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	16
Fitusiran: First Approval	16
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis	16
Drugs in Development to Treat IgA Nephropathy	15
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions	15
The Potential of RNA Therapeutics in Treating Cardiovascular Disease	15
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis	15
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	15
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	15
Tegileridine: First Approval	15
Elinzanetant: First Approval	15
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management	15
Systemic Therapy for Advanced Thyroid Cancer—New Personalized Options	15
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	15
Clesrovimab: First Approval	15
Ebronucimab: First Approval	15
Pirtobrutinib: First Approval	15
Vonoprazan: A Review in Helicobacter pylori Infection	14
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy	14
Anticoagulation in Chronic Kidney Disease	14
Correction to: Nirmatrelvir Plus Ritonavir: First Approval	14
Correction to: Daridorexant: First Approval	14
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	14
Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	14